Literature DB >> 26244318

Rociletinib in EGFR-Mutated Non-Small-Cell Lung Cancer.

Lecia V Sequist, Lindsey Rolfe, Andrew R Allen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26244318     DOI： 10.1056/NEJMc1506831

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  25 in total

Review 1.  Treatment of EGFR T790M-Positive Non-Small Cell Lung Cancer.

Authors:  Joan Rou-En Choo; Chee-Seng Tan; Ross A Soo
Journal:  Target Oncol       Date:  2018-04       Impact factor: 4.493

Review 2.  The next tier of EGFR resistance mutations in lung cancer.

Authors:  Hannah L Tumbrink; Alena Heimsoeth; Martin L Sos
Journal:  Oncogene       Date:  2020-10-15       Impact factor: 9.867

Review 3.  Hyperglycaemia Induced by Novel Anticancer Agents: An Undesirable Complication or a Potential Therapeutic Opportunity?

Authors:  Rashmi R Shah
Journal:  Drug Saf       Date:  2017-03       Impact factor: 5.606

4.  A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non-small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations.

Authors:  Helena A Yu; Alexander Spira; Leora Horn; Jared Weiss; Howard West; Giuseppe Giaccone; Tracey Evans; Ronan J Kelly; Bhardwaj Desai; Andrew Krivoshik; Diarmuid Moran; Srinivasu Poondru; Fei Jie; Kouji Aoyama; Anne Keating; Geoffrey R Oxnard
Journal:  Clin Cancer Res       Date:  2017-09-27       Impact factor: 12.531

5.  Discovery of a Potent and Mutant-Selective EGFR Inhibitor that Overcomes T790M-Mediated Resistance in Lung Cancer.

Authors:  Dong Ha Kim; Yun Jung Choi; Seon Ye Kim; Jung-Eun Lee; Ki Jung Sung; Young Hoon Sung; Woo Sung Kim; Sung-Eun Kim; Hyung Chul Ryu; Jae Sun Kim; Lu Guangying; Chang-Min Choi; Jin Kyung Rho; Jae Cheol Lee
Journal:  Target Oncol       Date:  2018-06       Impact factor: 4.493

6.  Phase I study of the combination of quinacrine and erlotinib in patients with locally advanced or metastatic non small cell lung cancer.

Authors:  Priyanka Bhateja; Afshin Dowlati; Neelesh Sharma
Journal:  Invest New Drugs       Date:  2017-10-02       Impact factor: 3.850

Review 7.  Targeting EGFR in Lung Cancer: Current Standards and Developments.

Authors:  Asunción Díaz-Serrano; Pablo Gella; Elisabeth Jiménez; Jon Zugazagoitia; Luis Paz-Ares Rodríguez
Journal:  Drugs       Date:  2018-06       Impact factor: 9.546

Review 8.  Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors.

Authors:  Shuhang Wang; Yongping Song; Feifei Yan; Delong Liu
Journal:  Front Med       Date:  2016-12-23       Impact factor: 4.592

9.  Telmisartan Facilitates the Anticancer Effects of CARP-1 Functional Mimetic and Sorafenib in Rociletinib Resistant Non-small Cell Lung Cancer.

Authors:  Sunil Kumar Surapaneni; Ebony Nottingham; Arindam Mondal; Nilkumar Patel; Peggy Arthur; Aragaw Gebeyehu; Anil Kumar Kalvala; Arun K Rishi; Mandip Singh
Journal:  Anticancer Res       Date:  2021-09-01       Impact factor: 2.480

10.  Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA.

Authors:  Jeffrey C Thompson; Stephanie S Yee; Andrea B Troxel; Samantha L Savitch; Ryan Fan; David Balli; David B Lieberman; Jennifer D Morrissette; Tracey L Evans; Joshua Bauml; Charu Aggarwal; John A Kosteva; Evan Alley; Christine Ciunci; Roger B Cohen; Stephen Bagley; Susan Stonehouse-Lee; Victoria E Sherry; Elizabeth Gilbert; Corey Langer; Anil Vachani; Erica L Carpenter
Journal:  Clin Cancer Res       Date:  2016-09-06       Impact factor: 12.531
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.